Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting
Cambridge, Mass., May 6, 2015 – Editas Medicine, a leading genome editing company, today announced six abstracts have been accepted for one oral and five poster presentations at the 18 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentations will detail data from research programs across a broad range of disease areas, including cancer, hematologic (blood) and ophthalmic (eye) diseases. The meeting will take place May 13-16 at the Hyatt Regency in New Orleans.
Following is a schedule of Editas’ poster and oral presentations:
Cas9-Mediated Genome Editing in Hematopoietic Stem/Progenitor Cells
Authors: Jennifer L. Gori, G. Grant Welstead, McKensie A. Collins, Justin W. Fang, Ari E. Friedland, David Bumcrot
Date/Time: Wednesday, May 13 at 5:15 p.m.
Session Info: Poster Session: Gene Targeting and Gene Correction I
Biophysical Characterization and Direct Delivery of S. Pyogenes Cas9 Ribonucleoprotein Complexes
Authors: William Selleck, Grant Welstead, Justin Fang, McKensie Collins, David Bumcrot, Hari Jayaram
Date/Time: Wednesday, May 13 at 5:15 p.m.
Session Info: Poster Session: Chemical/Molecular Conjugates
Characterization of Cas9-Mediated Genome Editing in Human T Cells
Authors: G. Grant Welstead, Jennifer Gori, Justin Fang, McKensie Collins, Will Selleck, Ari Friedland, Hari Jayaram, David Bumcrot
Date/Time: Thursday, May 14 at 5:30 p.m.
Session Info: Poster Session: Gene Targeting and Gene Correction II
Therapeutic Editing of the HBB Locus Using the Endogenous HBD Locus as a Donor Template
Authors: Cecilia Cotta-Ramusino, Tanushree Phadke, Morgan Maeder, David Bumcrot
Date/Time: Friday, May 15 at 5:30 p.m.
Session Info: Poster Session: Gene Targeting and Gene Correction III
Staphyloccocus aureus Cas9: An Alternative Cas9 for Genome Editing Applications
Authors: Ari E. Friedland, Alex Sousa, McKensie Collins, Morgan L. Maeder, Hari Jayaram, Grant G. Welstead, Sebastian Gloskowski, David Bumcrot
Date/Time: Friday, May 15 at 5:30 pm
Session Info: Poster Session: Gene Targeting and Gene Correction III
Therapeutic Correction of an LCA-Causing Splice Defect in the CEP290 Gene by CRISPR/Cas-Mediated Genome Editing
Authors: Morgan L. Maeder, Shen Shen, Erin R. Burnight, Sebastian Gloskowski, Rina Mepani, Ari E. Friedland, Hari Jayaram, Greg Gotta, Budd A. Tucker, David Bumcrot
Date/Time: Saturday, May 16 at 11 a.m.
Session Info: Simultaneous Oral Abstract Sessions: Gene Editing and Gene Regulation III
About Editas Medicine
Editas Medicine is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically driven diseases. For more information, visit www.editasmedicine.com.
###
Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
